FTC files administrative complaint vs. PBMs alleging artificially inflated insulin prices

The Federal Trade Commission announced it has filed an administrative complaint against three pharmacy benefit managers alleging “anticompetitive and unfair” rebate practices that have artificially inflated the price of insulin drugs.
The complaint accuses the three pharmacy benefit managers (PBMs) — CVS Health’s Caremark, Cigna’s Express Scripts and UnitedHealth Group’s OptumRx — and their affiliated group purchasing organizations (GPOs) — Zinc Health Services, Ascent Health Services and Emisar Pharma Services, respectively — of “engaging

The Federal Trade Commission announced it has filed an administrative complaint against three pharmacy benefit managers alleging “anticompetitive and unfair” rebate practices that have artificially inflated the price of insulin drugs.
The complaint accuses the three pharmacy benefit managers (PBMs) — CVS Health’s Caremark, Cigna’s Express Scripts and UnitedHealth Group’s OptumRx — and their affiliated group purchasing organizations (GPOs) — Zinc Health Services, Ascent Health Services and Emisar Pharma Services, respectively — of “engaging